Although CAR-T cell therapy* is providing hope for patients with relapsed refractory diffuse large B-cell lymphoma, there is still no established standard treatment for about half of them and the prognosis is known to be so poor that life expectancy is only 6 months. In a situation where a new treatment for these patients was needed, domestic medical staff opened up the possibility and expressed hope.
* Collect only T cells, which are immune cells, from the patient’s blood, install CAR, a substance that detects cancer cells, undergo genetic modification, and then inject it back into the patient. Diffuse large B-cell lymphoma that is refractory to existing treatment or has relapsed, aged 25 or younger. It is applicable to B-cell acute lymphoblastic leukemia.
At Seoul National University Hospital, Professors Ko Young-il and Park Chang-hee of the Department of Hematology-Oncology and the joint research team of the Korean Clinical Research Consortium for Lymphoma (CISL) developed a new anti-cancer chemotherapy based on ‘BTK inhibitor’, a targeted anti-cancer drug used to treat low-grade lymphoma, and confirmed its effectiveness. revealed.
Diffuse large B-cell lymphoma is a type of aggressive lymphoma that progresses rapidly, and more than half of malignant lymphomas are of this type. It is treated with chemotherapy using a combination of anticancer drugs such as rituximab.4 out of 10 people do not respond to primary treatment or experience recurrence after treatmentdo.
Accordingly, the research team used anticancer therapy (R2A therapy) using a combination of the targeted anticancer drug ‘BTK inhibitor (acalabrutinib)’, the immunomodulating anticancer drug ‘lenalidomide’ used to treat multiple myeloma, and the C20 targeted anticancer drug ‘rituximab’. developed. Afterwards, a single-group phase 2 clinical trial was conducted in which this therapy was administered to 66 patients and the treatment response was monitored.
According to the research team, after an average follow-up period of about 9 months, The objective response rate (ORR) was 54.5%, with more than half of all patients responding to treatment with a reduction in tumor size or complete disappearance of the tumor.showed. Especially when the tumor disappears completely. Complete response (CR) occurred in 3 out of 10 patients (31.8%). appear. also The 1-year progression-free survival (PFS) rate is 33.1% of all patients, meaning that 1 in 3 patients will have no tumor progression for 1 year.It appeared.
Furthermore, the research team conducted additional DNA, RNA, and protein-based biomarker analysis to identify the patient group that would be most effective with R2A therapy, and the results showed that patients with MYD88 mutation or activated NF-κB protein action showed a significant treatment response. confirmed that
The research team found that BTK inhibitors are effective not only in low-risk lymphoma but also in low-risk lymphoma. It is also effective in treating aggressive lymphoma, and combination therapy based on this anticancer drug can be a new approach to completely cure relapsed refractory diffuse large B-cell lymphoma.He emphasized.
Professor Ko Young-il said, “BTK inhibitor-based anti-cancer treatment is Plays an important role in the treatment of patients with relapsed refractory diffuse large B-cell lymphoma who have failed CAR-T treatment“We will do it,” he said. “As verified by this study, If R2A therapy is combined with the recently developed dual antibody therapy and CAR-T therapy, it is expected that another treatment that increases survival rates can be developed.“It will happen,” he said.
Copyright © Health Kyunghyang. Reproduction and redistribution prohibited.
Tags: anticancer drug combination relapsed refractory diffuse large Bcell lymphoma
-
